GH1 and endometrial carcinoma: As previously proposed for mammary and endometrial carcinoma, use of a single dual antagonist to hGH and hPRL may be a preferred approach to inhibit the oncogenic actions of these hormones in HCC as opposed to use of specific antagonists individually.